Cargando…

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis

BACKGROUND: It is now widely accepted that radiotherapy (RT) can provoke a systemic immune response, which gives a strong rationale for the combination of RT and immune checkpoint inhibitors (ICIs). However, RT is a double-edged sword that not only enhances systemic antitumor immune response, but al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jing, Ni, Tingting, Deng, Rong, Li, Yan, Zhong, Qin, Tang, Fei, Zhang, Qi, Fang, Chunju, Xue, Yingbo, Zha, Yan, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040597/ https://www.ncbi.nlm.nih.gov/pubmed/36993952 http://dx.doi.org/10.3389/fimmu.2023.1065510

Ejemplares similares

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy
por: Zhong, Qin, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
por: Yang, Xue-Gang, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report
por: Cheng, Yuan, et al.
Publicado: (2022)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2022)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
por: Bi, Jianping, et al.
Publicado: (2022)

The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis
por: Mei, Ting, et al.
Publicado: (2023)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Comparison of dynamic changes in the peripheral CD8(+) T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy
por: Wei, Hui, et al.
Publicado: (2022)

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
por: Guan, Shasha, et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis
por: Liu, Maobai, et al.
Publicado: (2022)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
por: Jiang, Nan, et al.
Publicado: (2023)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vic573kjpe22t28jh0rm0jaao